Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Monotherapy Ezetimib...
The recommended dose of ezetimibe tablets is 10 mg once daily. Ezetimibe tablets can be administered with or without food. Ezetimibe tablets may be administered with a statin (in patients with primary hyperlipidemia) or with fenofibrate (in patients with mixed hyperlipidemia) for incremental effect. For convenience, the daily dose of ezetimibe tablets may be taken at the same time as the statin or fenofibrate, acc...
Ezetimibe tablets, USP 10 mg, are white to almost white, oval tablets debossed with "SZ" on one side and '499' on other side. They are supplied as follows: NDC 71205-145-30 bottles of 30 NDC 71205-145-60 bottles of 60 NDC 71205-145-90 bottles of 90 Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature.] Protect from moisture.
www.fda.gov/medwatchTherapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.
Monotherapy
Ezetimibe tablets, administered alone, are indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia.
Combination Therapy with HMG-CoA Reductase Inhibitors (Statins)
Ezetimibe tablets, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), are indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia.
Combination Therapy with Fenofibrate
Ezetimibe tablets, administered in combination with fenofibrate, are indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in adult patients with mixed hyperlipidemia.
The combination of ezetimibe and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
Ezetimibe tablets are indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.
The effect of ezetimibe tablets on cardiovascular morbidity and mortality has not been determined.
Ezetimibe tablets have not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.
The recommended dose of ezetimibe tablets is 10 mg once daily.
Ezetimibe tablets can be administered with or without food.
Ezetimibe tablets may be administered with a statin (in patients with primary hyperlipidemia) or with fenofibrate (in patients with mixed hyperlipidemia) for incremental effect. For convenience, the daily dose of ezetimibe tablets may be taken at the same time as the statin or fenofibrate, according to the dosing recommendations for the respective medications.
Dosing of ezetimibe tablets should occur either ≥2 hours before or ≥4 hours after administration of a bile acid sequestrant [see Drug Interactions (7.4)].
No dosage adjustment is necessary in patients with mild hepatic impairment [see Warnings and Precautions (5.4)].
No dosage adjustment is necessary in patients with renal impairment [seeClinical Pharmacology (12.3) ]. When given with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring [see Use In Specific Populations (8.6)]
No dosage adjustment is necessary in geriatric patients [see Clinical Pharmacology (12.3)].
10-mg tablets are white to almost white, oval tablets debossed with "SZ" on one side and "499" on other side.
Ezetimibe is contraindicated in the following conditions:
Concurrent administration of ezetimibe with a specific statin or fenofibrate should be in accordance with the product labeling for that medication.
In controlled clinical monotherapy studies, the incidence of consecutive elevations (≥3 X the upper limit of normal [ULN]) in hepatic transaminase levels was similar between ezetimibe (0.5%) and placebo (0.3%).
In controlled clinical combination studies of ezetimibe initiated concurrently with a statin, the incidence of consecutive elevations (≥3 X ULN) in hepatic transaminase levels was 1.3% for patients treated with ezetimibe administered with statins and 0.4% for patients treated with statins alone. These elevations in transaminases were generally asymptomatic, not associated with cholestasis, and returned to baseline after discontinuation of therapy or with continued treatment. When ezetimibe is co-administered with a statin, liver tests should be performed at initiation of therapy and according to the recommendations of the statin. Should an increase in ALT or AST ≥3 X ULN persist, consider withdrawal of ezetimibe and/or the statin.
In clinical trials, there was no excess of myopathy or rhabdomyolysis associated with ezetimibe compared with the relevant control arm (placebo or statin alone). However, myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs. In clinical trials, the incidence of creatine phosphokinase (CPK) >10 X ULN was 0.2% for ezetimibe vs 0.1% for placebo, and 0.1% for ezetimibe co-administered with a statin vs 0.4% for statins alone. Risk for skeletal muscle toxicity increases with higher doses of statin, advanced age (>65), hypothyroidism, renal impairment, and depending on the statin used, concomitant use of other drugs.
In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported. Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe. However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates. Ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected. The presence of muscle symptoms and a CPK level >10 X the ULN indicates myopathy.
Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate to severe hepatic impairment, ezetimibe is not recommended in these patients [seeClinical Pharmacology (12.3)].
The following serious adverse reactions are discussed in greater detail in other sections of the label:
Monotherapy Studies
In the ezetimibe controlled clinical trials database (placebo-controlled) of 2396 patients with a median treatment duration of 12 weeks (range 0 to 39 weeks), 3.3% of patients on ezetimibe and 2.9% of patients on placebo discontinued due to adverse reactions. The most common adverse reactions in the group of patients treated with ezetimibe that led to treatment discontinuation and occurred at a rate greater than placebo were:
The most commonly reported adverse reactions (incidence ≥2% and greater than placebo) in the ezetimibe monotherapy controlled clinical trial database of 2396 patients were: upper respiratory tract infection (4.3%), diarrhea (4.1%), arthralgia (3.0%), sinusitis (2.8%), and pain in extremity (2.7%).
Statin Co-Administration Studies
In the ezetimibe + statin controlled clinical trials database of 11,308 patients with a median treatment duration of 8 weeks (range 0 to 112 weeks), 4.0% of patients on ezetimibe + statin and 3.3% of patients on statin alone discontinued due to adverse reactions. The most common adverse reactions in the group of patients treated with ezetimibe + statin that led to treatment discontinuation and occurred at a rate greater than statin alone were:
The most commonly reported adverse reactions (incidence ≥2% and greater than statin alone) in the ezetimibe + statin controlled clinical trial database of 11,308 patients were: nasopharyngitis (3.7%), myalgia (3.2%), upper respiratory tract infection (2.9%), arthralgia (2.6%) and diarrhea (2.5%).
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
Monotherapy
In 10 double-blind, placebo-controlled clinical trials, 2396 patients with primary hyperlipidemia (age range 9 to 86 years, 50% women, 90% Caucasians, 5% Blacks, 3% Hispanics, 2% Asians) and elevated LDL-C were treated with ezetimibe 10 mg/day for a median treatment duration of 12 weeks (range 0 to 39 weeks).
Adverse reactions reported in ≥2% of patients treated with ezetimibe and at an incidence greater than placebo in placebo-controlled studies of ezetimibe, regardless of causality assessment, are shown in Table 1.
Body System/Organ Class | Ezetimibe 10 mg | Placebo |
Gastrointestinal disorders | ||
Diarrhea | 4.1 | 3.7 |
General disorders and administration site conditions | ||
Fatigue | 2.4 | 1.5 |
Infections and infestations | ||
Influenza | 2 | 1.5 |
Sinusitis | 2.8 | 2.2 |
Upper respiratory tract infection | 4.3 | 2.5 |
Musculoskeletal and connective tissue disorders | ||
Arthralgia | 3 | 2.2 |
Pain in extremity | 2.7 | 2.5 |
The frequency of less common adverse reactions was comparable between ezetimibe and placebo.
Combination with a Statin
In 28 double-blind, controlled (placebo or active-controlled) clinical trials, 11,308 patients with primary hyperlipidemia (age range 10 to 93 years, 48% women, 85% Caucasians, 7% Blacks, 4% Hispanics, 3% Asians) and elevated LDL-C were treated with ezetimibe 10 mg/day concurrently with or added to on-going statin therapy for a median treatment duration of 8 weeks (range 0 to 112 weeks).
The incidence of consecutive increased transaminases (≥3 X ULN) was higher in patients receiving ezetimibe administered with statins (1.3%) than in patients treated with statins alone (0.4%) [see Warnings and Precautions (5.2)].
Clinical adverse reactions reported in ≥2% of patients treated with ezetimibe + statin and at an incidence greater than statin, regardless of causality assessment, are shown in Table 2.
Body System/Organ Class | All Statins*
| Ezetimibe + All Statins
|
Gastrointestinal disorders | ||
Diarrhea | 2.2 | 2.5 |
General disorders and administration site conditions | ||
Fatigue | 1.6 | 2 |
Infections and infestations | ||
Influenza | 2.1 | 2.2 |
Nasopharyngitis | 3.3 | 3.7 |
Upper respiratory tract infection | 2.8 | 2.9 |
Musculoskeletal and connective tissue disorders | ||
Arthralgia | 2.4 | 2.6 |
Back pain | 2.3 | 2.4 |
Myalgia | 2.7 | 3.2 |
Pain in extremity | 1.9 | 2.1 |
* All Statins = all doses of all statins
Combination with Fenofibrate
This clinical study involving 625 patients with mixed dyslipidemia (age range 20 to 76 years, 44% women, 79% Caucasians, 0.1% Blacks, 11% Hispanics, 5% Asians) treated for up to 12 weeks and 576 patients treated for up to an additional 48 weeks evaluated co-administration of ezetimibe and fenofibrate. This study was not designed to compare treatment groups for infrequent events. Incidence rates (95% CI) for clinically important elevations (≥3 X ULN, consecutive) in hepatic transaminase levels were 4.5% (1.9, 8.8) and 2.7% (1.2, 5.4) for fenofibrate monotherapy (n=188) and ezetimibe co-administered with fenofibrate (n=183), respectively, adjusted for treatment exposure. Corresponding incidence rates for cholecystectomy were 0.6% (95% CI: 0%, 3.1%) and 1.7% (95% CI: 0.6%, 4.0%) for fenofibrate monotherapy and ezetimibe co-administered with fenofibrate, respectively [see Drug Interactions (7.3)]. The numbers of patients exposed to co-administration therapy as well as fenofibrate and ezetimibe monotherapy were inadequate to assess gallbladder disease risk. There were no CPK elevations >10 X ULN in any of the treatment groups.
Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following additional adverse reactions have been identified during post-approval use of ezetimibe:
Hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria; erythema multiforme; arthralgia; myalgia; elevated creatine phosphokinase; myopathy/rhabdomyolysis [see Warnings and Precautions (5.3)]; elevations in liver transaminases; hepatitis; abdominal pain; thrombocytopenia; pancreatitis; nausea; dizziness; paresthesia; depression; headache; cholelithiasis; cholecystitis.
[See Clinical Pharmacology (12.3).]
Caution should be exercised when using ezetimibe and cyclosporine concomitantly due to increased exposure to both ezetimibe and cyclosporine. Cyclosporine concentrations should be monitored in patients receiving ezetimibe and cyclosporine.
The degree of increase in ezetimibe exposure may be greater in patients with severe renal insufficiency. In patients treated with cyclosporine, the potential effects of the increased exposure to ezetimibe from concomitant use should be carefully weighed against the benefits of alterations in lipid levels provided by ezetimibe.
The efficacy and safety of co-administration of ezetimibe with fibrates other than fenofibrate have not been studied.
Fibrates may increase cholesterol excretion into the bile, leading to cholelithiasis. In a preclinical study in dogs, ezetimibe increased cholesterol in the gallbladder bile [see NONCLINICAL TOXICOLOGY(13.2)]. Co-administration of ezetimibe with fibrates other than fenofibrate is not recommended until use in patients is adequately studied.
If cholelithiasis is suspected in a patient receiving ezetimibe and fenofibrate, gallbladder studies are indicated and alternative lipid-lowering therapy should be considered [see ADVERSE REACTIONS (6.1) and the product labeling for fenofibrate].
Concomitant cholestyramine administration decreased the mean area under the curve (AUC) of total ezetimibe approximately 55%. The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.
If ezetimibe is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.
Pregnancy Category C:
There are no adequate and well-controlled studies of ezetimibe in pregnant women. Ezetimibe should be used during pregnancy only if the potential benefit justifies the risk to the fetus.
In oral (gavage) embryo-fetal development studies of ezetimibe conducted in rats and rabbits during organogenesis, there was no evidence of embryolethal effects at the doses tested (250, 500, 1000 mg/kg/day). In rats, increased incidences of common fetal skeletal findings (extra pair of thoracic ribs, unossified cervical vertebral centra, shortened ribs) were observed at 1000 mg/kg/day (~10 × the human exposure at 10 mg daily based on AUC0–24hr for total ezetimibe). In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 × the human exposure at 10 mg daily based on AUC0–24hr for total ezetimibe). Ezetimibe crossed the placenta when pregnant rats and rabbits were given multiple oral doses.
Multiple-dose studies of ezetimibe given in combination with statins in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. Reproductive findings occur at lower doses in combination therapy compared to monotherapy.
All statins are contraindicated in pregnant and nursing women. When ezetimibe is administered with a statin in a woman of childbearing potential, refer to the pregnancy category and product labeling for the statin [seeContraindications (4)].
It is not known whether ezetimibe is excreted into human breast milk. In rat studies, exposure to total ezetimibe in nursing pups was up to half of that observed in maternal plasma. Because many drugs are excreted in human milk, caution should be exercised when ezetimibe is administered to a nursing woman. Ezetimibe should not be used in nursing mothers unless the potential benefit justifies the potential risk to the infant.
The effects of ezetimibe co-administered with simvastatin (n=126) compared to simvastatin monotherapy (n=122) have been evaluated in adolescent boys and girls with heterozygous familial hypercholesterolemia (HeFH). In a multicenter, double-blind, controlled study followed by an open-label phase, 142 boys and 106 postmenarchal girls, 10 to 17 years of age (mean age 14.2 years, 43% females, 82% Caucasians, 4% Asian, 2% Blacks, 13% multi-racial) with HeFH were randomized to receive either ezetimibe co-administered with simvastatin or simvastatin monotherapy. Inclusion in the study required 1) a baseline LDL-C level between 160 and 400 mg/dL and 2) a medical history and clinical presentation consistent with HeFH. The mean baseline LDL-C value was 225 mg/dL (range: 161 to 351 mg/dL) in the ezetimibe co-administered with simvastatin group compared to 219 mg/dL (range: 149 to 336 mg/dL) in the simvastatin monotherapy group. The patients received co-administered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) or simvastatin monotherapy (10 mg, 20 mg, or 40 mg) for 6 weeks, co-administered ezetimibe and 40 mg simvastatin or 40 mg simvastatin monotherapy for the next 27 weeks, and open-label co-administered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter.
The results of the study at Week 6 are summarized in Table 3. Results at Week 33 were consistent with those at Week 6.
| Total-C | LDL-C | Apo B | Non-HDL-C | TG* | HDL-C | |
|---|---|---|---|---|---|---|
Mean percent difference between treatment groups | -12% | -15% | -12% | -14% | -2% | +0.1% |
95% Confidence Interval | (-15%, -9%) | (-18%, -12%) | (-15%, -9%) | (-17%, -11%) | (-9%, +4%) | (-3%, +3%) |
* For triglycerides, median % change from baseline
From the start of the trial to the end of Week 33, discontinuations due to an adverse reaction occurred in 7 (6%) patients in the ezetimibe co-administered with simvastatin group and in 2 (2%) patients in the simvastatin monotherapy group.
During the trial, hepatic transaminase elevations (two consecutive measurements for ALT and/or AST ≥3 X ULN) occurred in four (3%) individuals in the ezetimibe co-administered with simvastatin group and in two (2%) individuals in the simvastatin monotherapy group. Elevations of CPK (≥10 X ULN) occurred in two (2%) individuals in the ezetimibe co-administered with simvastatin group and in zero individuals in the simvastatin monotherapy group.
In this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on menstrual cycle length in girls.
Co-administration of ezetimibe with simvastatin at doses greater than 40 mg/day has not been studied in adolescents. Also, ezetimibe has not been studied in patients younger than 10 years of age or in pre-menarchal girls.
Based on total ezetimibe (ezetimibe + ezetimibe-glucuronide), there are no pharmacokinetic differences between adolescents and adults. Pharmacokinetic data in the pediatric population <10 years of age are not available.
Monotherapy Studies
Of the 2396 patients who received ezetimibe in clinical studies, 669 (28%) were 65 and older, and 111 (5%) were 75 and older.
Statin Co-Administration Studies
Of the 11,308 patients who received ezetimibe + statin in clinical studies, 3587 (32%) were 65 and older, and 924 (8%) were 75 and older.
No overall differences in safety and effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].
When used as monotherapy, no dosage adjustment of ezetimibe is necessary.
In the Study of Heart and Renal Protection (SHARP) trial of 9270 patients with moderate to severe renal impairment (6247 non-dialysis patients with median serum creatinine 2.5 mg/dL and median estimated glomerular filtration rate 25.6 mL/min/1.73 m2, and 3023 dialysis patients), the incidence of serious adverse events, adverse events leading to discontinuation of study treatment, or adverse events of special interest (musculoskeletal adverse events, liver enzyme abnormalities, incident cancer) was similar between patients ever assigned to ezetimibe 10 mg plus simvastatin 20 mg (n=4650) or placebo (n=4620) during a median follow-up of 4.9 years. However, because renal impairment is a risk factor for statin-associated myopathy, doses of simvastatin exceeding 20 mg should be used with caution and close monitoring when administered concomitantly with ezetimibe in patients with moderate to severe renal impairment.
Ezetimibe is not recommended in patients with moderate to severe hepatic impairment [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].
Ezetimibe given concomitantly with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic transaminase levels [see Contraindications (4) ; Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, 40 mg/day to 18 patients with primary hyperlipidemia for up to 56 days, and 40 mg/day to 27 patients with homozygous sitosterolemia for 26 weeks was generally well tolerated. One female patient with homozygous sitosterolemia took an accidental overdose of ezetimibe 120 mg/day for 28 days with no reported clinical or laboratory adverse events.
In the event of an overdose, symptomatic and supportive measures should be employed.
Ezetimibe is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. The chemical name of ezetimibe is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The molecular formula is C24H21F2NO3. Its molecular weight is 409.4 and its structural formula is:
Ezetimibe, USP is a white to off-white crystalline powder that is freely to very soluble in ethanol, methanol, and acetone and practically insoluble in water. Ezetimibe has a melting point of about 163°C and is stable at ambient temperature. Ezetimibe is available as a tablet for oral administration containing 10 mg of ezetimibe and the following inactive ingredients: croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.
Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. In a 2-week clinical study in 18 hypercholesterolemic patients, ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo. Ezetimibe had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E (in a study of 113 patients), and did not impair adrenocortical steroid hormone production (in a study of 118 patients).
The cholesterol content of the liver is derived predominantly from three sources. The liver can synthesize cholesterol, take up cholesterol from the blood from circulating lipoproteins, or take up cholesterol absorbed by the small intestine. Intestinal cholesterol is derived primarily from cholesterol secreted in the bile and from dietary cholesterol.
Ezetimibe has a mechanism of action that differs from those of other classes of cholesterol-reducing compounds (statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols.
Ezetimibe does not inhibit cholesterol synthesis in the liver, or increase bile acid excretion. Instead, ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of statins and of fenofibrate [see Clinical Studies (14.1)].
Clinical studies have demonstrated that elevated levels of total-C, LDL-C and Apo B, the major protein constituent of LDL, promote human atherosclerosis. In addition, decreased levels of HDL-C are associated with the development of atherosclerosis. Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C. Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and remnants, can also promote atherosclerosis. The independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.
Ezetimibe reduces total-C, LDL-C, Apo B, non-HDL-C, and TG, and increases HDL-C in patients with hyperlipidemia. Administration of ezetimibe with a statin is effective in improving serum total-C, LDL-C, Apo B, non-HDL-C, TG, and HDL-C beyond either treatment alone. Administration of ezetimibe with fenofibrate is effective in improving serum total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia as compared to either treatment alone. The effects of ezetimibe given either alone or in addition to a statin or fenofibrate on cardiovascular morbidity and mortality have not been established.
Absorption
After oral administration, ezetimibe is absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). After a single 10-mg dose of ezetimibe to fasted adults, mean ezetimibe peak plasma concentrations (Cmax) of 3.4 to 5.5 ng/mL were attained within 4 to 12 hours (Tmax). Ezetimibe-glucuronide mean Cmax values of 45 to 71 ng/mL were achieved between 1 and 2 hours (Tmax). There was no substantial deviation from dose proportionality between 5 and 20 mg. The absolute bioavailability of ezetimibe cannot be determined, as the compound is virtually insoluble in aqueous media suitable for injection.
Effect of Food on Oral Absorption
Concomitant food administration (high-fat or non-fat meals) had no effect on the extent of absorption of ezetimibe when administered as ezetimibe 10-mg tablets. The Cmax value of ezetimibe was increased by 38% with consumption of high-fat meals. Ezetimibe can be administered with or without food.
Distribution
Ezetimibe and ezetimibe-glucuronide are highly bound (>90%) to human plasma proteins.
Metabolism and Excretion
Ezetimibe is primarily metabolized in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary and renal excretion. Minimal oxidative metabolism (a phase I reaction) has been observed in all species evaluated.
In humans, ezetimibe is rapidly metabolized to ezetimibe-glucuronide. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10 to 20% and 80 to 90% of the total drug in plasma, respectively. Both ezetimibe and ezetimibe-glucuronide are eliminated from plasma with a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide. Plasma concentration-time profiles exhibit multiple peaks, suggesting enterohepatic recycling.
Following oral administration of 14C-ezetimibe (20 mg) to human subjects, total ezetimibe (ezetimibe + ezetimibe-glucuronide) accounted for approximately 93% of the total radioactivity in plasma. After 48 hours, there were no detectable levels of radioactivity in the plasma.
Approximately 78% and 11% of the administered radioactivity were recovered in the feces and urine, respectively, over a 10-day collection period. Ezetimibe was the major component in feces and accounted for 69% of the administered dose, while ezetimibe-glucuronide was the major component in urine and accounted for 9% of the administered dose.
Specific Populations
Geriatric Patients
In a multiple-dose study with ezetimibe given 10 mg once daily for 10 days, plasma concentrations for total ezetimibe were about 2-fold higher in older (≥65 years) healthy subjects compared to younger subjects.
Pediatric Patients
[See Use In Specific Populations (8.4) .]
Gender
In a multiple-dose study with ezetimibe given 10 mg once daily for 10 days, plasma concentrations for total ezetimibe were slightly higher (<20%) in women than in men.
Race
Based on a meta-analysis of multiple-dose pharmacokinetic studies, there were no pharmacokinetic differences between Black and Caucasian subjects. Studies in Asian subjects indicated that the pharmacokinetics of ezetimibe were similar to those seen in Caucasian subjects.
Hepatic Impairment
After a single 10-mg dose of ezetimibe, the mean AUC for total ezetimibe was increased approximately 1.7-fold in patients with mild hepatic impairment (Child-Pugh score 5 to 6), compared to healthy subjects. The mean AUC values for total ezetimibe and ezetimibe were increased approximately 3- to 4-fold and 5- to 6-fold, respectively, in patients with moderate (Child-Pugh score 7 to 9) or severe hepatic impairment (Child-Pugh score 10 to 15). In a 14-day, multiple-dose study (10 mg daily) in patients with moderate hepatic impairment, the mean AUC values for total ezetimibe and ezetimibe were increased approximately 4-fold on Day 1 and Day 14 compared to healthy subjects. Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, ezetimibe is not recommended in these patients [see Warnings and Precautions (5.4)].
Renal Impairment
After a single 10-mg dose of ezetimibe in patients with severe renal disease (n=8; mean CrCl ≤30 mL/min/1.73 m2), the mean AUC values for total ezetimibe, ezetimibe-glucuronide, and ezetimibe were increased approximately 1.5-fold, compared to healthy subjects (n=9).
Drug Interactions
[See also Drug Interactions (7)]
Ezetimibe had no significant effect on a series of probe drugs (caffeine, dextromethorphan, tolbutamide, and IV midazolam) known to be metabolized by cytochrome P450 (1A2, 2D6, 2C8/9 and 3A4) in a "cocktail" study of twelve healthy adult males. This indicates that ezetimibe is neither an inhibitor nor an inducer of these cytochrome P450 isozymes, and it is unlikely that ezetimibe will affect the metabolism of drugs that are metabolized by these enzymes.
| Co-Administered Drug and Dosing Regimen | Total Ezetimibe * | |
|---|---|---|
| Change in AUC | Change in Cmax | |
↑240% | ↑290% | |
Fenofibrate, 200 mg QD, 14 days | ↑48% | ↑64% |
Gemfibrozil, 600 mg BID, 7 days | ↑64% | ↑91% |
Cholestyramine, 4 g BID, 14 days | ↓55% | ↓4% |
Aluminum & magnesium hydroxide combination antacid, single dose§ | ↓4% | ↓30% |
Cimetidine, 400 mg BID, 7 days | ↑6% | ↑22% |
Glipizide, 10 mg, single dose | ↑4% | ↓8% |
Statins | ||
Lovastatin 20 mg QD, 7 days | ↑9% | ↑3% |
Pravastatin 20 mg QD, 14 days | ↑7% | ↑23% |
Atorvastatin 10 mg QD, 14 days | ↓2% | ↑12% |
Rosuvastatin 10 mg QD, 14 days | ↑13% | ↑18% |
Fluvastatin 20 mg QD, 14 days | ↓19% | ↑7% |
* Based on 10 mg dose of ezetimibe
‡ Post-renal transplant patients with mild impaired or normal renal function. In a different study, a renal transplant patient with severe renal insufficiency (creatinine clearance of 13.2 mL/min/1.73 m2) who was receiving multiple medications, including cyclosporine, demonstrated a 12-fold greater exposure to total ezetimibe compared to healthy subjects.
§ Supralox, 20 mL
| Co-Administered Drug and its Dosage Regimen | Ezetimibe Dosage Regimen | Change in AUC of Co-Administered Drug | Change in Cmax of Co-Administered Drug |
|---|---|---|---|
Warfarin, 25 mg single dose on day 7 | 10 mg QD, 11 days | ↓2% (R-warfarin) | ↑3% (R-warfarin) |
Digoxin, 0.5 mg single dose | 10 mg QD, 8 days | ↑2% | ↓7% |
Gemfibrozil, 600 mg BID, 7 days* | 10 mg QD, 7 days | ↓1% | ↓11% |
Ethinyl estradiol & Levonorgestrel, QD, 21 days | 10 mg QD, days 8 to 14 of 21d oral contraceptive cycle | Ethinyl estradiol | Ethinyl estradiol |
Glipizide, 10 mg on days 1 and 9 | 10 mg QD, days 2 to 9 | ↓3% | ↓5% |
Fenofibrate, 200 mg QD, 14 days | 10 mg QD, 14 days | ↑11% | ↑7% |
Cyclosporine, 100 mg single dose day 7 | 20 mg QD, 8 days | ↑15% | ↑10% |
Statins | |||
Lovastatin 20 mg QD, 7 days | 10 mg QD, 7 days | ↑19% | ↑3% |
Pravastatin 20 mg QD, 14 days | 10 mg QD, 14 days | ↓20% | ↓24% |
Atorvastatin 10 mg QD, 14 days | 10 mg QD, 14 days | ↓4% | ↑7% |
Rosuvastatin 10 mg QD, 14 days | 10 mg QD, 14 days | ↑19% | ↑17% |
Fluvastatin 20 mg QD, 14 days | 10 mg QD, 14 days | ↓39% | ↓27% |
A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 X the human exposure at 10 mg daily based on AUC0–24hr for total ezetimibe). A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 X the human exposure at 10 mg daily based on AUC0–24hr for total ezetimibe). There were no statistically significant increases in tumor incidences in drug-treated rats or mice.
No evidence of mutagenicity was observed in vitro in a microbial mutagenicity (Ames) test with Salmonella typhimurium and Escherichia coli with or without metabolic activation. No evidence of clastogenicity was observed in vitro in a chromosomal aberration assay in human peripheral blood lymphocytes with or without metabolic activation. In addition, there was no evidence of genotoxicity in the in vivo mouse micronucleus test.
In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 X the human exposure at 10 mg daily based on AUC0–24hr for total ezetimibe).
The hypocholesterolemic effect of ezetimibe was evaluated in cholesterol-fed Rhesus monkeys, dogs, rats, and mouse models of human cholesterol metabolism. Ezetimibe was found to have an ED50 value of 0.5 mcg/kg/day for inhibiting the rise in plasma cholesterol levels in monkeys. The ED50 values in dogs, rats, and mice were 7, 30, and 700 mcg/kg/day, respectively. These results are consistent with Ezetimibe being a potent cholesterol absorption inhibitor.
In a rat model, where the glucuronide metabolite of ezetimibe (SCH 60663) was administered intraduodenally, the metabolite was as potent as the parent compound (SCH 58235) in inhibiting the absorption of cholesterol, suggesting that the glucuronide metabolite had activity similar to the parent drug.
In 1-month studies in dogs given ezetimibe (0.03 to 300 mg/kg/day), the concentration of cholesterol in gallbladder bile increased ~2- to 4-fold. However, a dose of 300 mg/kg/day administered to dogs for one year did not result in gallstone formation or any other adverse hepatobiliary effects. In a 14-day study in mice given ezetimibe (0.3 to 5 mg/kg/day) and fed a low-fat or cholesterol-rich diet, the concentration of cholesterol in gallbladder bile was either unaffected or reduced to normal levels, respectively.
A series of acute preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting cholesterol absorption. Ezetimibe inhibited the absorption of 14C-cholesterol with no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or the fat-soluble vitamins A and D.
In 4- to 12-week toxicity studies in mice, ezetimibe did not induce cytochrome P450 drug metabolizing enzymes. In toxicity studies, a pharmacokinetic interaction of ezetimibe with statins (parents or their active hydroxy acid metabolites) was seen in rats, dogs, and rabbits.
Ezetimibe reduces total-C, LDL-C, Apo B, non-HDL-C, and TG, and increases HDL-C in patients with hyperlipidemia. Maximal to near maximal response is generally achieved within 2 weeks and maintained during chronic therapy.
Monotherapy
In two multicenter, double-blind, placebo-controlled, 12-week studies in 1719 patients with primary hyperlipidemia, ezetimibe significantly lowered total-C, LDL-C, Apo B, non-HDL-C, and TG, and increased HDL-C compared to placebo (see Table 6 ). Reduction in LDL-C was consistent across age, sex, and baseline LDL-C.
| Treatment Group | N | Total-C | LDL-C | Apo B | Non-HDL-C | TG | HDL-C | |
|---|---|---|---|---|---|---|---|---|
Study 1‡ | Placebo | 205 | +1 | +1 | -1 | +1 | -1 | -1 |
Ezetimibe | 622 | -12 | -18 | -15 | -16 | -7 | +1 | |
Study 2 | Placebo | 226 | +1 | +1 | -1 | +2 | +2 | -2 |
Ezetimibe | 666 | -12 | -18 | -16 | -16 | -9 | +1 | |
Pooled Data (Studies 1 & 2) | Placebo | 431 | 0 | +1 | -2 | +1 | 0 | -2 |
Ezetimibe | 1288 | -13 | -18 | -16 | -16 | -8 | +1 |
Combination with Statins
Ezetimibe Added to On-going Statin Therapy
In a multicenter, double-blind, placebo-controlled, 8-week study, 769 patients with primary hyperlipidemia, known coronary heart disease or multiple cardiovascular risk factors who were already receiving statin monotherapy, but who had not met their NCEP ATP II target LDL-C goal were randomized to receive either ezetimibe or placebo in addition to their on-going statin.
Ezetimibe, added to on-going statin therapy, significantly lowered total-C, LDL-C, Apo B, non-HDL-C, and TG, and increased HDL-C compared with a statin administered alone (see Table 7). LDL-C reductions induced by ezetimibe were generally consistent across all statins.
| Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C | TG | HDL-C |
|---|---|---|---|---|---|---|---|
On-going Statin + Placebo§ | 390 | -2 | -4 | -3 | -3 | -3 | +1 |
On-going Statin + Ezetimibe | 379 | -17 | -25 | -19 | -23 | -14 | +3 |
* Patients receiving each statin: 40% atorvastatin, 31% simvastatin, 29% others (pravastatin, fluvastatin, cerivastatin, lovastatin)
† For triglycerides, median % change from baseline
‡ Baseline - on a statin alone.
§ Ezetimibe + statin significantly reduced total-C, LDL-C, Apo B, non-HDL-C, and TG, and increased HDL-C compared to statin alone.
Ezetimibe Initiated Concurrently with a Statin
In four multicenter, double-blind, placebo-controlled, 12-week trials, in 2382 hyperlipidemic patients, ezetimibe or placebo was administered alone or with various doses of atorvastatin, simvastatin, pravastatin, or lovastatin.
When all patients receiving ezetimibe with a statin were compared to all those receiving the corresponding statin alone, ezetimibe significantly lowered total-C, LDL-C, Apo B, non-HDL-C, and TG, and, with the exception of pravastatin, increased HDL-C compared to the statin administered alone. LDL-C reductions induced by ezetimibe were generally consistent across all statins. (See footnote‡, Tables 8 to 11.)
| Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C | TG | HDL-C |
|---|---|---|---|---|---|---|---|
Placebo | 60 | +4 | +4 | +3 | +4 | -6 | +4 |
Ezetimibe | 65 | -14 | -20 | -15 | -18 | -5 | +4 |
Atorvastatin 10 mg | 60 | -26 | -37 | -28 | -34 | -21 | +6 |
Ezetimibe + Atorvastatin 10 mg | 65 | -38 | -53 | -43 | -49 | -31 | +9 |
Atorvastatin 20 mg | 60 | -30 | -42 | -34 | -39 | -23 | +4 |
Ezetimibe + Atorvastatin 20 mg | 62 | -39 | -54 | -44 | -50 | -30 | +9 |
Atorvastatin 40 mg | 66 | -32 | -45 | -37 | -41 | -24 | +4 |
Ezetimibe + Atorvastatin 40 mg | 65 | -42 | -56 | -45 | -52 | -34 | +5 |
Atorvastatin 80 mg | 62 | -40 | -54 | -46 | -51 | -31 | +3 |
Ezetimibe + Atorvastatin 80 mg | 63 | -46 | -61 | -50 | -58 | -40 | +7 |
Pooled data (All Atorvastatin Doses)‡ | 248 | -32 | -44 | -36 | -41 | -24 | +4 |
Pooled data (All Ezetimibe + Atorvastatin Doses) | 255 | -41 | -56 | -45 | -52 | -33 | +7 |
* For triglycerides, median % change from baseline
† Baseline - on no lipid-lowering drug
‡ Ezetimibe + all doses of atorvastatin pooled (10 to 80 mg) significantly reduced total-C, LDL-C, Apo B, non-HDL-C, and TG, and increased HDL-C compared to all doses of atorvastatin pooled (10 to 80 mg).
| Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C | TG | HDL-C |
|---|---|---|---|---|---|---|---|
Placebo | 70 | -1 | -1 | 0 | -1 | +2 | +1 |
Ezetimibe | 61 | -13 | -19 | -14 | -17 | -11 | +5 |
Simvastatin 10 mg | 70 | -18 | -27 | -21 | -25 | -14 | +8 |
Ezetimibe + Simvastatin 10 mg | 67 | -32 | -46 | -35 | -42 | -26 | +9 |
Simvastatin 20 mg | 61 | -26 | -36 | -29 | -33 | -18 | +6 |
Ezetimibe + Simvastatin 20 mg | 69 | -33 | -46 | -36 | -42 | -25 | +9 |
Simvastatin 40 mg | 65 | -27 | -38 | -32 | -35 | -24 | +6 |
Ezetimibe + Simvastatin 40 mg | 73 | -40 | -56 | -45 | -51 | -32 | +11 |
Simvastatin 80 mg | 67 | -32 | -45 | -37 | -41 | -23 | +8 |
Ezetimibe + Simvastatin 80 mg | 65 | -41 | -58 | -47 | -53 | -31 | +8 |
Pooled data (All Simvastatin Doses)‡ | 263 | -26 | -36 | -30 | -34 | -20 | +7 |
Pooled data (All Ezetimibe + Simvastatin Doses) | 274 | -37 | -51 | -41 | -47 | -29 | +9 |
* For triglycerides, median % change from baseline
† Baseline - on no lipid-lowering drug
‡ Ezetimibe + all doses of simvastatin pooled (10 to 80 mg) significantly reduced total-C, LDL-C, Apo B, non-HDL-C, and TG, and increased HDL-C compared to all doses of simvastatin pooled (10 to 80 mg).
| Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C | TG | HDL-C |
|---|---|---|---|---|---|---|---|
Placebo | 65 | 0 | -1 | -2 | 0 | -1 | +2 |
Ezetimibe | 64 | -13 | -20 | -15 | -17 | -5 | +4 |
Pravastatin 10 mg | 66 | -15 | -21 | -16 | -20 | -14 | +6 |
Ezetimibe + Pravastatin 10 mg | 71 | -24 | -34 | -27 | -32 | -23 | +8 |
Pravastatin 20 mg | 69 | -15 | -23 | -18 | -20 | -8 | +8 |
Ezetimibe + Pravastatin 20 mg | 66 | -27 | -40 | -31 | -36 | -21 | +8 |
Pravastatin 40 mg | 70 | -22 | -31 | -26 | -28 | -19 | +6 |
Ezetimibe + Pravastatin 40 mg | 67 | -30 | -42 | -32 | -39 | -21 | +8 |
Pooled data (All Pravastatin Doses)‡ | 205 | -17 | -25 | -20 | -23 | -14 | +7 |
Pooled data (All Ezetimibe + Pravastatin Doses) | 204 | -27 | -39 | -30 | -36 | -21 | +8 |
* For triglycerides, median % change from baseline
† Baseline - on no lipid-lowering drug
‡ Ezetimibe + all doses of pravastatin pooled (10 to 40 mg) significantly reduced total-C, LDL-C, Apo B, non-HDL-C, and TG compared to all doses of pravastatin pooled (10 to 40 mg).
| Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C | TG | HDL-C |
|---|---|---|---|---|---|---|---|
Placebo | 64 | +1 | 0 | +1 | +1 | +6 | 0 |
Ezetimibe | 72 | -13 | -19 | -14 | -16 | -5 | +3 |
Lovastatin 10 mg | 73 | -15 | -20 | -17 | -19 | -11 | +5 |
Ezetimibe + Lovastatin 10 mg | 65 | -24 | -34 | -27 | -31 | -19 | +8 |
Lovastatin 20 mg | 74 | -19 | -26 | -21 | -24 | -12 | +3 |
Ezetimibe + Lovastatin 20 mg | 62 | -29 | -41 | -34 | -39 | -27 | +9 |
Lovastatin 40 mg | 73 | -21 | -30 | -25 | -27 | -15 | +5 |
Ezetimibe + Lovastatin 40 mg | 65 | -33 | -46 | -38 | -43 | -27 | +9 |
Pooled data (All Lovastatin Doses)‡ | 220 | -18 | -25 | -21 | -23 | -12 | +4 |
Pooled data (All Ezetimibe + Lovastatin Doses) | 192 | -29 | -40 | -33 | -38 | -25 | +9 |
* For triglycerides, median % change from baseline
† Baseline - on no lipid-lowering drug
‡ Ezetimibe + all doses of lovastatin pooled (10 to 40 mg) significantly reduced total-C, LDL-C, Apo B, non-HDL-C, and TG, and increased HDL-C compared to all doses of lovastatin pooled (10 to 40 mg).
Combination with Fenofibrate
In a multicenter, double-blind, placebo-controlled, clinical study in patients with mixed hyperlipidemia, 625 patients were treated for up to 12 weeks and 576 for up to an additional 48 weeks. Patients were randomized to receive placebo, ezetimibe alone, 160 mg fenofibrate alone, or ezetimibe and 160 mg fenofibrate in the 12-week study. After completing the 12-week study, eligible patients were assigned to ezetimibe co-administered with fenofibrate or fenofibrate monotherapy for an additional 48 weeks.
Ezetimibe co-administered with fenofibrate significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared to fenofibrate administered alone. The percent decrease in TG and percent increase in HDL-C for ezetimibe co-administered with fenofibrate were comparable to those for fenofibrate administered alone (see Table 12).
| Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | TG | HDL-C | Non-HDL-C |
|---|---|---|---|---|---|---|---|
Placebo | 63 | 0 | 0 | -1 | -9 | +3 | 0 |
Ezetimibe | 185 | -12 | -13 | -11 | -11 | +4 | -15 |
Fenofibrate 160 mg | 188 | -11 | -6 | -15 | -43 | +19 | -16 |
Ezetimibe + Fenofibrate 160 mg | 183 | -22 | -20 | -26 | -44 | +19 | -30 |
The changes in lipid endpoints after an additional 48 weeks of treatment with ezetimibe co-administered with fenofibrate or with fenofibrate alone were consistent with the 12-week data displayed above.
A study was conducted to assess the efficacy of ezetimibe in the treatment of HoFH. This double-blind, randomized, 12-week study enrolled 50 patients with a clinical and/or genotypic diagnosis of HoFH, with or without concomitant LDL apheresis, already receiving atorvastatin or simvastatin (40 mg). Patients were randomized to one of three treatment groups, atorvastatin or simvastatin (80 mg), ezetimibe administered with atorvastatin or simvastatin (40 mg), or ezetimibe administered with atorvastatin or simvastatin (80 mg). Due to decreased bioavailability of ezetimibe in patients concomitantly receiving cholestyramine [see Drug Interactions (7.4) ], ezetimibe was dosed at least 4 hours before or after administration of resins. Mean baseline LDL-C was 341 mg/dL in those patients randomized to atorvastatin 80 mg or simvastatin 80 mg alone and 316 mg/dL in the group randomized to ezetimibe plus atorvastatin 40 or 80 mg or simvastatin 40 or 80 mg. Ezetimibe, administered with atorvastatin or simvastatin (40 and 80 mg statin groups, pooled), significantly reduced LDL-C (21%) compared with increasing the dose of simvastatin or atorvastatin monotherapy from 40 to 80 mg (7%). In those treated with ezetimibe plus 80 mg atorvastatin or with ezetimibe plus 80 mg simvastatin, LDL-C was reduced by 27%.
A study was conducted to assess the efficacy of ezetimibe in the treatment of homozygous sitosterolemia. In this multicenter, double-blind, placebo-controlled, 8-week trial, 37 patients with homozygous sitosterolemia with elevated plasma sitosterol levels (>5 mg/dL) on their current therapeutic regimen (diet, bile-acid-binding resins, statins, ileal bypass surgery and/or LDL apheresis), were randomized to receive ezetimibe (n=30) or placebo (n=7). Due to decreased bioavailability of ezetimibe in patients concomitantly receiving cholestyramine [see Drug Interactions (7.4)] , ezetimibe was dosed at least 2 hours before or 4 hours after resins were administered. Excluding the one subject receiving LDL apheresis, ezetimibe significantly lowered plasma sitosterol and campesterol, by 21% and 24% from baseline, respectively. In contrast, patients who received placebo had increases in sitosterol and campesterol of 4% and 3% from baseline, respectively. For patients treated with ezetimibe, mean plasma levels of plant sterols were reduced progressively over the course of the study. The effects of reducing plasma sitosterol and campesterol on reducing the risks of cardiovascular morbidity and mortality have not been established.
Reductions in sitosterol and campesterol were consistent between patients taking ezetimibe concomitantly with bile acid sequestrants (n=8) and patients not on concomitant bile acid sequestrant therapy (n=21).
Limitations of Use
The effect of ezetimibe on cardiovascular morbidity and mortality has not been determined.
Ezetimibe tablets, USP 10 mg, are white to almost white, oval tablets debossed with "SZ" on one side and '499' on other side. They are supplied as follows:
NDC 71205-145-30 bottles of 30
NDC 71205-145-60 bottles of 60
NDC 71205-145-90 bottles of 90
Storage
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature.] Protect from moisture.
See FDA-Approved Patient Labeling (Patient Information) .
Patients should be advised to adhere to their National Cholesterol Education Program (NCEP)-recommended diet, a regular exercise program, and periodic testing of a fasting lipid panel.
All patients starting therapy with ezetimibe should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or weakness. The risk of this occurring is increased when taking certain types of medication. Patients should discuss all medication, both prescription and over-the-counter, with their physician.
Liver tests should be performed when ezetimibe tablets are added to statin therapy and according to statin recommendations.
Women of childbearing age should be advised to use an effective method of birth control to prevent pregnancy while using ezetimibe tablets added to statin therapy. Discuss future pregnancy plans with your patients, and discuss when to stop combination ezetimibe tablets and statin therapy if they are trying to conceive. Patients should be advised that if they become pregnant they should stop taking combination ezetimibe tablets and statin therapy and call their healthcare professional.
Women who are breastfeeding should be advised to not use ezetimibe tablets added to statin therapy. Patients who have a lipid disorder and are breastfeeding should be advised to discuss the options with their healthcare professionals.
Ezetimibe Tablets, USP
(ee-ZET-ah-mybe)
Patient Information
Read this information carefully before you start taking ezetimibe tablets and each time you get more ezetimibe tablets. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about ezetimibe tablets, ask your doctor. Only your doctor can determine if ezetimibe tablets are right for you.
What is ezetimibe tablet?
Ezetimibe tablet is a medicine used to lower levels of total cholesterol and LDL (bad) cholesterol in the blood. Ezetimibe tablets are for patients who cannot control their cholesterol levels by diet and exercise alone. It can be used by itself or with other medicines to treat high cholesterol. You should stay on a cholesterol-lowering diet while taking this medicine.
Ezetimibe tablets work to reduce the amount of cholesterol your body absorbs. Ezetimibe tablets do not help you lose weight. Ezetimibe tablets have not been shown to prevent heart disease or heart attacks.
For more information about cholesterol, see the "What should I know about high cholesterol?" section that follows.
Who should not take ezetimibe tablets?
Ezetimibe tablets have not been studied in children under age 10.
What should I tell my doctor before and while taking ezetimibe tablets?
Tell your doctor about any prescription and non-prescription medicines you are taking or plan to take, including natural or herbal remedies.
Tell your doctor about all your medical conditions including allergies.
Tell your doctor if you:
How should I take ezetimibe tablets?
See your doctor regularly to check your cholesterol level and to check for side effects. Your doctor may do blood tests to check your liver before you start taking ezetimibe tablets with a statin and during treatment.
What are the possible side effects of ezetimibe tablets?
In clinical studies patients reported few side effects while taking ezetimibe tablets. These included diarrhea, joint pains, and feeling tired.
Patients have experienced severe muscle problems while taking ezetimibe tablets, usually when ezetimibe tablets was added to a statin drug. If you experience unexplained muscle pain, tenderness, or weakness while taking ezetimibe tablets, contact your doctor immediately. You need to do this promptly, because on rare occasions, these muscle problems can be serious, with muscle breakdown resulting in kidney damage.
Additionally, the following side effects have been reported in general use: allergic reactions (which may require treatment right away) including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing, rash, and hives; raised red rash, sometimes with target-shaped lesions; joint pain; muscle aches; alterations in some laboratory blood tests; liver problems; stomach pain; inflammation of the pancreas; nausea; dizziness; tingling sensation; depression; headache; gallstones; inflammation of the gallbladder.
Tell your doctor if you are having these or any other medical problems while on ezetimibe tablets. For a complete list of side effects, ask your doctor or pharmacist.
What should I know about high cholesterol?
Cholesterol is a type of fat found in your blood. Your total cholesterol is made up of LDL and HDL cholesterol.
LDL cholesterol is called "bad" cholesterol because it can build up in the wall of your arteries and form plaque. Over time, plaque build-up can cause a narrowing of the arteries. This narrowing can slow or block blood flow to your heart, brain, and other organs. High LDL cholesterol is a major cause of heart disease and one of the causes for stroke.
HDL cholesterol is called "good" cholesterol because it keeps the bad cholesterol from building up in the arteries.
Triglycerides also are fats found in your blood.
General information about ezetimibe tablets
Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use ezetimibe tablets for a condition for which it was not prescribed. Do not give ezetimibe tablets to other people, even if they have the same condition you have. It may harm them.
This summarizes the most important information about ezetimibe tablets. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ezetimibe tablets that is written for health professionals.
Inactive ingredients:
Croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.
Finished Drug Product Manufactured by
Lek Pharmaceuticals d.d.
SI-1526 Ljubljana, Slovenia for
Sandoz Inc., Princeton, NJ 08540
Repackaged by:
Proficient Rx, LP.
Thousand Oaks, CA 91320
Rev. September 2016
NDC 71205-145-30
Ezetimibe Tablets, USP
10 mg
Rx Only
30 Tablets
| Class | Version | Type | Effective |
|---|---|---|---|
| EZETIMIBE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 91774e91-b249-45e3-8ff8-4b5db2927a69 | Product name | 1 | 20230718 |
| 93a156a6-903b-1690-4dc3-a57adfaa8c1a | Product name | 9 | 20230322 |
| c8f25656-847a-4de8-96a7-06bf98d83c2b | Product name | 1 | 20210916 |
| b249faa8-b784-47ef-8ad4-031ef248fa73 | Product name | 1 | 20200626 |
| c4422d73-8e69-1539-606a-32a25fa00ebc | Product name | 4 | 20190926 |
| 46fdf265-6d5a-1bfb-93db-d82a4ea8aa81 | Product name | 1 | 20140508 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 71205-145-30 | Ezetimibe | 30 in 1 BOTTLE | TABLET | 30 | 3 | |
| 71205-145-60 | Ezetimibe | 60 in 1 BOTTLE | TABLET | 60 | 3 | |
| 71205-145-90 | Ezetimibe | 90 in 1 BOTTLE | TABLET | 90 | 3 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 71205-145-30 | EA - Each | 71205-145 | 7cf96db5-edc9-41c3-b221-28184f5385d9 | 1 | 2019-02-13 |
| 0781-5690-05 | EA - Each | 0781-5690 | a20df6b3-9452-438d-94cd-952082a47318 | 1 | 2017-07-07 |
| 0781-5690-31 | EA - Each | 0781-5690 | 61ecf5d1-4c52-46f4-bb60-12788c92a8f4 | 1 | 2017-07-07 |
| 0781-5690-92 | EA - Each | 0781-5690 | 7a3ae5e9-9d5e-49cb-9b48-314894661e78 | 1 | 2017-07-07 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 71205-145 | 71205-145-30, 71205-145-60, 71205-145-90 |
| 0781-5690 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| EZETIMIBE | EOR26LQQ24 | ACTIB |
| CROSCARMELLOSE SODIUM | M28OL1HH48 | IACT |
| LACTOSE MONOHYDRATE | EWQ57Q8I5X | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| MICROCRYSTALLINE CELLULOSE | OP1R32D61U | IACT |
| HYPROMELLOSE 2910 (15 MPA.S) | 36SFW2JZ0W | IACT |
| SODIUM LAURYL SULFATE | 368GB5141J | IACT |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A203931-001 | EZETIMIBE | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 |
| Application-product | TE code |
|---|---|
| A203931-001 | AB |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | A203931-001 | EZETIMIBE | 10MG | TABLET / ORAL | AB | 2017-06-12 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A203931-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A203931-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A203931-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A203931-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A203931-001 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A203931-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A203931-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A203931-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A203931-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A203931-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A203931-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A203931-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A203931-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A203931-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A203931-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A203931-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A203931-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A203931-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A203931-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A203931-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A203931-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A203931-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A203931-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A203931-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A203931-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A203931-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A203931-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A203931-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A203931-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A203931-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A203931-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A203931-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A203931-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A203931-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A203931-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A203931-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A203931-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A203931-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A203931-001 | AB | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A203931-001 | AB | 1 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ezetimibe | EZETIMIBE | Proficient Rx LP | 5cbd9bce-e02d-440f-95d5-4eb958d2f4f3 | 2019-10-01 | Warnings, Adverse reactions | 71205-145-30 71205-145-60 71205-145-90 71205-145 71205014530 71205014590 71205014560 4d2909bd-31fd-4ddc-99b5-2fc99b35f5d4 5cbd9bce-e02d-440f-95d5-4eb958d2f4f3 |
Adverse event summaries are temporarily unavailable. Other product information remains available.